Predictive significance of MPT-driven necrosis-related genes signature in gastric cancer and their impact on the tumor microenvironment
- 17 December 2024
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 27 (7) , 3015-3028
Abstract
Background Gastric cancer (GC) presents significant management challenges. MPT-driven necrosis (MPTDN) plays a significant role in various conditions, but its connection with GC is unclear. This study aimed to investigate the predictive significance of MPTDN-related genes (MPTDNRGs) in GC and their effect on the tumor immune microenvironment (TIME). Methods RNA sequencing data for GC were sourced from TCGA and GEO databases. The mutation profiles and MPTDNRG expression between tumor and normal samples were assessed. Prognostic mRNAs were identified using univariate Cox regression and LASSO regression. GC patients were classified into high- and low-risk groups according to risk scores, followed by survival analysis and evaluation of correlations between MPTDN score and clinicopathological features, functional pathway, TIME, and responses to immunotherapy. Results MPTDNRGs exhibited a 64% mutation rate in GC, with 22 showing significant expression differences. Univariate Cox and LASSO regression identified 15 independently prognostic MPTDNRGs. The prognostic risk model stratified patients into two groups, revealing significant differences in overall and disease-free survival. A nomogram incorporating the signature and clinical characteristics showed strong specificity and sensitivity in predicting prognosis. The MPTDN score was significantly associated with clinical characteristics, functional pathways, and TIME. scRNA-seq analysis indicated higher MPTDN-signature expression in CD8 + T cells, malignant cells, and myofibroblasts. TIDE analysis suggested high-risk patients have reduced responses to immunotherapy, while low-risk patients could benefit more. Importantly, validation using urothelial carcinoma data confirmed a better prognosis for low-risk patients with immunotherapy. Conclusion This study highlights the importance of MPTDN-related signatures in predicting GC prognosis and guiding therapeutic decisions.Keywords
Funding Information
- Natural Science Foundation of Guangdong Province (2021A1515012368)
This publication has 38 references indexed in Scilit:
- Regulatory T cells in gastric cancer: Key controllers from pathogenesis to therapyCancer Treatment Reviews, 2023
- Advances in cancer immunotherapiesCell, 2023
- T follicular helper cells in cancerTrends in Cancer, 2023
- Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical TrialsJAMA Oncology, 2021
- NK Cells in the Tumor Microenvironment2020
- Engineering Macrophages for Cancer Immunotherapy and Drug DeliveryAdvanced Materials, 2020
- Dissecting the Single-Cell Transcriptome Network Underlying Gastric Premalignant Lesions and Early Gastric CancerCell Reports, 2019
- Monocyte heterogeneity and functions in cancerJournal of Leukocyte Biology, 2019
- CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A reviewJournal of Cellular Physiology, 2018
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010